LCM
VRTX icon

LVM Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LVM Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Sell
24,986
-844
-3% -$374K 1.04% 29
2026
Q1 		$11.5M Buy
25,830
+55
+0.2% +$25.6K 1.09% 29
2025
Q4 		$11.7M Sell
25,775
-65
-0.3% -$28K 1.09% 29
2025
Q3 		$10.1M Sell
25,840
-4,230
-14% -$1.77M 0.97% 30
2025
Q2 		$13.4M Buy
30,070
+157
+0.5% +$72.3K 1.39% 22
2025
Q1 		$14.5M Sell
29,913
-470
-2% -$219K 1.61% 18
2024
Q4 		$12.2M Buy
30,383
+370
+1% +$172K 1.32% 25
2024
Q3 		$14.1M Hold
30,013
– – 1.6% 20
2024
Q2 		$14.1M Sell
30,013
-402
-1% -$174K 1.6% 20
2024
Q1 		$12.7M Buy
30,415
+315
+1% +$133K 1.5% 24
2023
Q4 		$12.2M Buy
30,100
+45
+0.1% +$16.6K 1.57% 21
2023
Q3 		$10.5M Buy
30,055
+675
+2% +$236K 1.47% 23
2023
Q2 		$10.3M Sell
29,380
-1,150
-4% -$387K 1.38% 26
2023
Q1 		$9.62M Sell
30,530
-2,590
-8% -$777K 1.33% 29
2022
Q4 		$9.56M Sell
33,120
-1,240
-4% -$378K 1.39% 29
2022
Q3 		$9.95M Sell
34,360
-2,140
-6% -$616K 1.52% 25
2022
Q2 		$10.3M Buy
36,500
+3,384
+10% +$906K 1.49% 25
2022
Q1 		$8.64M Buy
33,116
+1,270
+4% +$301K 1.14% 33
2021
Q4 		$6.99M Buy
31,846
+321
+1% +$62.4K 0.93% 37
2021
Q3 		$5.72M Buy
31,525
+645
+2% +$126K 0.86% 37
2021
Q2 		$6.23M Buy
30,880
+1,695
+6% +$355K 0.95% 36
2021
Q1 		$6.27M Buy
29,185
+400
+1% +$87.9K 1.02% 33
2020
Q4 		$6.8M Buy
+28,785
New +$6.6M 1.15% 31

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

LVM Capital Management's VRTX Position: Q2 2026 in Review

LVM Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q2 2026, selling an estimated $374K and leaving 24,986 shares worth $12.4M. The position accounts for 1.04% of the portfolio, ranked #29.

LVM Capital Management first reported a position in VRTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $14.5M in Q1 2025. 734 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LVM Capital Management held 24,986 shares of Vertex Pharmaceuticals worth $12.4M as of Q2 2026.
  • LVM Capital Management sold 844 Vertex Pharmaceuticals shares in Q2 2026, an estimated $374K.
  • Vertex Pharmaceuticals made up 1.04% of LVM Capital Management's portfolio in Q2 2026, its #29 holding.
  • LVM Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • LVM Capital Management's Vertex Pharmaceuticals position peaked at $14.5M in Q1 2025.
  • 734 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LVM Capital Management's 13F filing for Q2 2026, filed 9 Jul 2026.